Invasive fungal infections, predominantly caused by Candida and Aspergillus species, represent a major global mortality burden that is increasingly threatened by escalating resistance to primary antifungal classes such as azoles, echinocandins, and polyenes. This convergent crisis is clearly exemplified by the simultaneous global rise of multidrug-resistant Candida auris and the emergence of pan-azole-resistant Aspergillus fumigatus driven by environmental agricultural fungicide use. To bridge the gap between isolated resistance mechanisms and broader epidemiological trends, this review synthesises contemporary data across four core themes: molecular resistance pathways (including CYP51A, FKS, and ERG11 mutations, alongside efflux and biofilm-associated resistance), the clade-structured transmission dynamics of C. auris, the environmental selection of azole-resistant A. fumigatus, and the therapeutic pipeline of novel agents like olorofim, ibrexafungerp, fosmanogepix, and rezafungin. Ultimately, the manuscript argues that fungal resistance must be managed as a complex "One Health" systems phenomenon spanning hospitals, farms, and the environment, requiring harmonised global surveillance, robust stewardship, and a reconceptualisation of invasive mycoses as a central priority within the global antimicrobial resistance agenda.